Literature DB >> 26880444

Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.

Harindra Rajasekeran1, Yuliya Lytvyn2, David Z I Cherney3.   

Abstract

Inhibition of sodium-glucose cotransporter 2 causes both glycosuria and natriuresis, leading to reductions in hyperglycemia, body weight, blood pressure, and proteinuria. The recently published EMPA-REG OUTCOME study demonstrated significant cardiovascular and mortality benefits of sodium-glucose cotransporter 2 inhibition with empagliflozin in patients with type 2 diabetes and established cardiovascular disease, and may suggest a broader role for sodium-glucose cotransporter 2 inhibition in patients with heart failure.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26880444     DOI： 10.1016/j.kint.2015.12.038

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  40 in total

Review 1.  Does Elevated Glucose Promote Atherosclerosis? Pros and Cons.

Authors:  Karin E Bornfeldt
Journal:  Circ Res       Date:  2016-07-08       Impact factor: 17.367

Review 2.  Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.

Authors:  André J Scheen
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

3.  Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.

Authors:  Harindra Rajasekeran; Heather N Reich; Michelle A Hladunewich; Daniel Cattran; Julie A Lovshin; Yuliya Lytvyn; Petter Bjornstad; Vesta Lai; Josephine Tse; Leslie Cham; Syamantak Majumder; Bridgit B Bowskill; M Golam Kabir; Suzanne L Advani; Ian W Gibson; Manish M Sood; Andrew Advani; David Z I Cherney
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-15

Review 4.  The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.

Authors:  Saeeda Fatima; Ayesha Jameel; Fnu Ayesha; Dhananjai J Menzies
Journal:  Clin Cardiol       Date:  2017-08-25       Impact factor: 2.882

Review 5.  Implications of the EMPA-REG Trial for Clinical Care and Research.

Authors:  Angeliki M Stamatouli; Silvio E Inzucchi
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

Review 6.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

Review 7.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

8.  Cardio-renal protection with empagliflozin.

Authors:  Richard J MacIsaac; George Jerums; Elif I Ekinci
Journal:  Ann Transl Med       Date:  2016-10

Review 9.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Authors:  Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

10.  The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Ya Luo; Kai Lu; Gang Liu; Jing Wang; Irakoze Laurent; Xiaoli Zhou
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.